BWC2562 / Bugworks - LARVOL DELTA

Bugworks Research Inc. to Present Poster at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023, in Geneva, Switzerland (PRNewswire) - "Bugworks Research...is presenting the research findings on its novel, best-in-class, dual-acting adenosine antagonists BWC2094 and BWC2562 with the potential to treat a variety of hard-to-treat cancers, at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2023 in Geneva, Switzerland on 7th December. The poster highlights two lead molecules discovered from structure and property-guided drug discovery platform....BWC2094 and BWC2562 demonstrate synergistic activity in combination with approved cancer drugs in human peripheral blood assays and proprietary patient-derived ex vivo tumor explant platform as measured by a reduction in the tumor density and increased apoptosis/necrosis....Based on the totality of evidence, BWC2094 is ready for IND submission."

Preclinical • Oncology